Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Associations between pregnancy-related factors and birth characteristics with risk of rare uterine cancer subtypes: a Nordic population-based case-control study.
Abril J, Trabert B, Troisi R, Grotmol T, Ekbom A, Engeland A, Gissler M, Glimelius I, Madanat-Harjuoja L, Gulbech Ording A, Sørensen HT, Tretli S, Bjørge T. Abril J, et al. Among authors: glimelius i. Cancer Causes Control. 2024 May;35(5):741-747. doi: 10.1007/s10552-023-01832-6. Epub 2023 Dec 22. Cancer Causes Control. 2024. PMID: 38129544 Free PMC article.
Validation of a prediction model for post-chemotherapy fibrosis in nonseminoma patients.
Gerdtsson A, Torisson G, Thor A, Grenabo Bergdahl A, Almås B, Håkansson U, Törnblom M, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Larsen SM, Holmberg G, Wahlqvist R, Tandstad T, Cohn-Cedermark G, Ståhl O, Kjellman A. Gerdtsson A, et al. Among authors: glimelius i. BJU Int. 2023 Sep;132(3):329-336. doi: 10.1111/bju.16040. Epub 2023 May 20. BJU Int. 2023. PMID: 37129962
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Jerkeman M, Kolstad A, Hutchings M, Pasanen A, Meriranta L, Niemann CU, Kragh Jørgensen RR, El-Galaly TC, Riise J, Leppä S, Christensen JH, Sonnevi K, Pedersen LB, Wader KF, Glimelius I. Jerkeman M, et al. Among authors: glimelius i. Blood Adv. 2024 Jan 23;8(2):407-415. doi: 10.1182/bloodadvances.2023011920. Blood Adv. 2024. PMID: 38113470 Free PMC article. Clinical Trial.
Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours.
Gerdtsson A, Negaard HFS, Almås B, Bergdahl AG, Cohn-Cedermark G, Glimelius I, Halvorsen D, Haugnes HS, Hedlund A, Hellström M, Holmberg G, Karlsdóttir Á, Kjellman A, Larsen SM, Thor A, Wahlqvist R, Ståhl O, Tandstad T. Gerdtsson A, et al. Among authors: glimelius i. BJU Int. 2024 Jun;133(6):717-724. doi: 10.1111/bju.16289. Epub 2024 Jan 31. BJU Int. 2024. PMID: 38293778
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Malinverni C, Bernardelli A, Glimelius I, Mirandola M, Smedby KE, Tisi MC, Giné E, Albertsson-Lindblad A, Marin-Niebla A, Di Rocco A, Moita F, Sciarra R, Bašić-Kinda S, Hess G, Ohler A, Eskelund CW, Re A, Ferrarini I, Kolstad A, Räty R, Quaglia FM, Eyre TA, Scapinello G, Stefani PM, Morello L, Nassi L, Hohaus S, Ragaini S, Zilioli VR, Bruna R, Cocito F, Arcari A, Jerkeman M, Visco C. Malinverni C, et al. Among authors: glimelius i. Blood. 2024 Aug 29;144(9):1001-1009. doi: 10.1182/blood.2023023525. Blood. 2024. PMID: 38754055
Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies.
Argirion I, Pfeiffer RM, Proietti C, Coghill AE, Yu KJ, Middeldorp JM, Sarathkumara YD, Hsu WL, Chien YC, Lou PJ, Wang CP, Rothman N, Lan Q, Chen CJ, Mbulaiteye SM, Jarrett RF, Glimelius I, Smedby KE, Hjalgrim H, Hildesheim A, Doolan DL, Liu Z. Argirion I, et al. Among authors: glimelius i. Cancer Epidemiol Biomarkers Prev. 2023 May 1;32(5):687-696. doi: 10.1158/1055-9965.EPI-22-0452. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 36788424 Free PMC article.
118 results